Hospital Groups Cheer, Private Cancer Docs Deplore CMS’s Decision to End Deep Cut in 340B Hospitals’ Drug Payments

Centers for Medicare & Medicaid Services wordmark
340B hospitals are happy that CMS has decided to end a deep cut in the hospitals' Medicare drug reimbursement. Private oncology practices call the decision "“an outrageous dereliction of duty."

Groups that represent 340B hospitals praised the Biden administration’s decision Friday to end a deep cut in the hospitals’ Medicare Part B drug reimbursement in place since 2018. They urged the government to swiftly make 340B hospitals whole for their

Read More »

HRSA’s 340B Program Website Gets a New Look

HRSA 340B drug pricing program screenshots
HRSA refreshed its 340B drug pricing program website last week, the first major change in the site's appearance in about four years.

The U.S. Health Resources and Services Administration (HRSA) Office of Pharmacy Affairs (OPA), the unit within the Health and Human Services Department (HHS) that runs the 340B drug discount program, refreshed the OPA site late last week. This is the

Read More »

News Alert

181 House Members Prod HHS to Start Fining Drug Makers for “Unlawful” 340B Overcharges Involving Contract Pharmacies

East elevation of the U.S. Capitol building
181 bipartisan U.S. House members on Friday urged HHS to quickly fine all drug manufacturers that deny 340B pricing when covered entities use contract pharmacies.

One hundred eighty-one U.S. House members—144 Democrats and 37 Republicans—urged the Biden administration on Friday to quickly impose civil monetary penalties against all drug manufacturers that restrict access to 340B pricing when covered entities use contract pharmacies.

“Manufacturers have received

Read More »

Breaking News

In Big Win For 340B Hospitals, CMS Will Reverse Massive Drug Reimbursement Cut for 2023 and Seeks Input on Potential Remedies for Prior Years

340B provider groups strongly criticized the Centers for Medicare & Medicaid Services’ draft guidance for Medicare drug price negotiations.

The U.S. Centers for Medicare and Medicaid Services “fully anticipate[s]” applying a Medicare Part B reimbursement rate next year of average sales price ASP plus 6% to drugs and biologicals purchased through the 340B program, CMS announced late this afternoon.

Read More »

House GOP Task Force Apparently Takes a Pass on Making 340B Recommendations

Rep. Kevin Hern (R-OK) seated
A House GOP task force subcommittee chaired by Rep. Kevin Hern (R-Okla.) apparently has decided not to recommend 340B policies the party can advance if its takes control of the House following the November elections.

A U.S. House Republican task force assigned to develop proposals the party can advance if the GOP takes the majority in the November elections apparently chose not to make recommendations for the 340B program.

The Healthy Future Task Force’s affordability

Read More »

Feds Ask Appeals Court to Uphold HRSA’s 340B Program Violation Letters to Novo Nordisk and Sanofi

Seal of the U.S. Court of Appeals for the Third Circuit
The federal government wants the U.S. Third Circuit Court of Appeals to partially uphold and partially overturn a lower court's opinion in Novo Nordisk and Sanofi's consolidated 340B contract pharmacy cases.

A federal district judge was right to rule last November that drug makers Novo Nordisk and Sanofi may not tie strings to 340B pricing when providers use contract pharmacies, the federal government told a federal appeals court in Philadelphia last

Read More »

HHS Warns Pharmacies Not to Turn Away Women Requesting Abortion Medication

U.S. Dept. of Health and Human Services Office for Civil RIghts Guidance to Nation's Retail Pharmacies title page
HHS issued guidance to retail pharmacies about their legal duty to fill prescriptions for drugs that can end or prevent pregnancy.

The U.S. Department of Health and Human Services issued guidance to retail pharmacies yesterday about their “unique role … in ensuring access to comprehensive reproductive health care services”—including filling prescriptions for drugs that can end or prevent pregnancy.

Mifepristone and

Read More »

Merck Becomes Eighth Drug Maker to Sue HRSA in Defense of 340B Contract Pharmacy Restrictions

Merck flag with flag of the United States of America
Merck is the eighth drug manufacturer to sue HRSA in defense of conditions on 340B pricing when covered entities use contract pharmacies.

Drug manufacturer Merck sued the federal government on Friday over the government’s May 6 letter telling the company its conditions on 340B pricing when hospitals and health centers use contract pharmacies are illegal. The government warned Merck it could be

Read More »

PhRMA and J&J File Amicus Briefs in Support of Novartis and United Therapeutics

U.S. District Judge Dabney Friedrich seated at a hearing
PhRMA and Johnson & Johnson filed briefs backing Novartis and United Therapeutics's appeals of U.S. District Judge Dabney Friedrich’s ruling in their 340B contract pharmacy lawsuits.

Pharmaceutical Research and Manufacturers of America and drug maker Johnson & Johnson each filed a friend of the court brief in June backing Novartis and United Therapeutics in those two companies’ appeals of a federal district judge’s November decision that

Read More »

Senate Democratic Drug Pricing Bill Buoyed by Large Savings Estimate

Congressional Budget Office logo
Spending on pharmaceuticals in the 340B drug discount program went from nearly $7 billion in 2010 to $44 billion by 2021—a 19% annual increase—according to preliminary Congressional Budget Office estimates released this week.

U.S. Senate Democrats’ revamped drug pricing legislation would lower the federal deficit by $287 billion over 10 years, the nonpartisan Congressional Budget Office said late last week.

Last November, CBO estimated that drug pricing language in the House-passed Build Back

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live